文献速递肿瘤 PET/CT核素与放射性配体治疗

基于[68Ga]Ga-PSMA-11 PET/CT总存活肿瘤负荷的早期分子影像反应评估可独立预测[177Lu]Lu-PSMA-617放射性配体治疗的总生存

Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-11-02

本研究在前瞻性患者登记(REALITY研究,NCT04833517)中分析66例接受[177Lu]Lu-PSMA-617放射性配体治疗的转移性去势抵抗性前列腺癌(mCRPC)患者,于首周期前及第二周期后行[68Ga]Ga-PSMA-11 PET/CT,以总病灶PSMA(TLP)变化评估分子影像反应。结果显示分子影像部分缓解(PR)者中位总生存24.6个月,其余患者(疾病稳定或进展)为10.7个月,多因素分析中分子影像反应为总生存的独立预测因子(p=0.002),优于基于PSA的生化反应评估。

要点

  • 66例mCRPC患者中,分子影像PR 40/66(60.6%)、SD 19/66(28.7%)、PD 7/66(10.6%)。
  • 分子影像PR者中位OS 24.6个月,SD或PD者10.7个月。
  • 多因素分析中分子影像反应独立预测OS(p=0.002),生化反应不显著(p=0.515)。

核心结论

  • 全身分子影像衍生生物标志物总病灶PSMA(TLP)的早期变化可独立预测[177Lu]Lu-PSMA-617放射性配体治疗mCRPC的总生存,优于传统基于PSA的反应评估;作者认为TLP可能被视为比常用血清PSA更出色和先进的PSMA-RLT监测生物标志物。

研究设计与样本

  • 研究分析了前瞻性患者登记(REALITY研究,NCT04833517)中66例接受[177Lu]Lu-PSMA-617放射性配体治疗的mCRPC患者。
  • 患者在首周期前及第二周期后接受[68Ga]Ga-PSMA-11 PET/CT扫描,通过半自动全身肿瘤分割测定总病灶PSMA(TLP)。
  • 分子影像反应通过TLP变化及改良PERCIST标准评估,生化反应用标准血清PSA及PCWG3标准评估;采用单因素和多因素分析评估各反应评估方法及基线参数与OS的关联。

主要发现

  • 分子影像评估显示PR 40/66(60.6%)、SD 19/66(28.7%)、PD 7/66(10.6%)。
  • 生化反应评估显示PR 34/66(51.5%)、SD 20/66(30.3%)、PD 12/66(18.2%)。
  • 两种反应评估在49/66(74.3%)病例中一致。
  • 单因素分析中,分子影像反应(p=0.001)和生化反应(p=0.008)以及两项基线特征(ALP和ECOG)均与OS显著相关。
  • 分子影像PR患者中位OS为24.6个月,其余患者(SD或PD)为10.7个月。

关键数值与推荐

  • 分子影像反应采用TLP变化及改良PERCIST标准评估,生化反应采用标准血清PSA及PCWG3标准评估。
  • 分子影像PR 40/66(60.6%)、SD 19/66(28.7%)、PD 7/66(10.6%);生化PR 34/66(51.5%)、SD 20/66(30.3%)、PD 12/66(18.2%)。
  • 分子影像PR患者中位OS 24.6个月 vs 其余患者(SD或PD)10.7个月。
  • 单因素分析中分子影像反应p=0.001、生化反应p=0.008、ALP和ECOG与OS显著相关;多因素分析中分子影像反应p=0.002、生化反应p=0.515。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In patients with metastatic castration-resistant prostate cancer (mCRPC) treated with prostate-specific membrane antigen-targeted radioligand therapy (PSMA-RLT), the predictive value of PSMA PET/CT-derived response is still under investigation. Early molecular imaging response based on total viable tumor burden and its association with overall survival (OS) was explored in this study. METHODS: Sixty-six mCRPC patients who received [177Lu]Lu-PSMA-617 RLT within a prospective patient registry (REALITY Study, NCT04833517) were analyzed. Patients received a [68Ga]Ga-PSMA-11 PET/CT scan before the first and after the second cycle of PSMA-RLT. Total lesion PSMA (TLP) was determined by semiautomatic whole-body tumor segmentation. Molecular imaging response was assessed by change in TLP and modified PERCIST criteria. Biochemical response was assessed using standard serum PSA and PCWG3 criteria. Both response assessment methods and additional baseline parameters were analyzed regarding their association with OS by univariate and multivariable analysis. RESULTS: By molecular imaging, 40/66 (60.6%) patients showed partial remission (PR), 19/66 (28.7%) stable disease (SD), and 7/66 (10.6%) progressive disease (PD). Biochemical response assessment revealed PR in 34/66 (51.5%) patients, SD in 20/66 (30.3%), and PD in 12/66 (18.2%). Response assessments were concordant in 49/66 (74.3%) cases. On univariate analysis, both molecular and biochemical response (p = 0.001 and 0.008, respectively) as well as two baseline characteristics (ALP and ECOG) were each significantly associated with OS. The median OS of patients showing molecular PR was 24.6 versus 10.7 months in the remaining patients (with SD or PD). On multivariable analysis molecular imaging response remained an independent predictor of OS (p = 0.002), eliminating biochemical response as insignificant (p = 0.515). CONCLUSION: The new whole-body molecular imaging-derived biomarker, early change of total lesion PSMA (TLP), independently predicts overall survival in [177Lu]Lu-PSMA-617 RLT in mCRPC, outperforming conventional PSA-based response assessment. TLP might be considered a more distinguished and advanced biomarker for monitoring PSMA-RLT over commonly used serum PSA.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Rosar F, Wenner F, Khreish F, et al. Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapy. Eur J Nucl Med Mol Imaging. 2021. PMID: 34725725. doi:10.1007/s00259-021-05594-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。